Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Current Leases (2022 - 2025)

Historic Current Leases for Caribou Biosciences (CRBU) over the last 4 years, with Q3 2025 value amounting to $2.7 million.

  • Caribou Biosciences' Current Leases rose 12809.85% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 12809.85%. This contributed to the annual value of $1.4 million for FY2024, which is 1883.33% up from last year.
  • Per Caribou Biosciences' latest filing, its Current Leases stood at $2.7 million for Q3 2025, which was up 12809.85% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' Current Leases ranged from a high of $2.7 million in Q3 2025 and a low of $825000.0 during Q1 2022
  • Moreover, its 4-year median value for Current Leases was $1.2 million (2024), whereas its average is $1.3 million.
  • As far as peak fluctuations go, Caribou Biosciences' Current Leases soared by 342.41% in 2024, and later surged by 12809.85% in 2025.
  • Over the past 4 years, Caribou Biosciences' Current Leases (Quarter) stood at $966000.0 in 2022, then increased by 24.22% to $1.2 million in 2023, then grew by 18.83% to $1.4 million in 2024, then skyrocketed by 88.43% to $2.7 million in 2025.
  • Its Current Leases was $2.7 million in Q3 2025, compared to $2.3 million in Q2 2025 and $1.9 million in Q1 2025.